India's anti-obesity drug market has grown more than fourfold in the last five years
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle diseases and increased affordability. Semaglutide, particularly Rybelsus from Novo Nordisk, dominates the market, accounting for 69% of sales. The introduction of Mounjaro by Eli Lilly has further fueled acceptance, with Novo Nordisk planning to launch Wegovy soon.
RSS News
Economic times
0 thoughts on “India's anti-obesity drug market has grown more than fourfold in the last five years”
Leave a Reply
Your email address will not be published. Required fields are marked *
